Fluconazole and itraconazole: current status and prospects for antifungal therapy.
作者信息
Sugar A M
机构信息
Boston University School of Medicine, Evans Memorial Department of Clinical Research, Massachusetts.
出版信息
Curr Clin Top Infect Dis. 1993;13:74-98.
PMID:8397919
Abstract
摘要
相似文献
1
Fluconazole and itraconazole: current status and prospects for antifungal therapy.氟康唑和伊曲康唑：抗真菌治疗的现状与前景
Curr Clin Top Infect Dis. 1993;13:74-98.
2
[Commonly used antifungal agents in the treatment of systemic mycoses].[治疗系统性真菌病常用的抗真菌药物]
Rev Clin Esp. 1995 Oct;195 Suppl 3:58-65.
3
[Therapy of invasive mycoses in neutropenic patients with hematologic system diseases].[血液系统疾病中性粒细胞减少患者侵袭性真菌病的治疗]
Dtsch Med Wochenschr. 1998 Feb 13;123(7):191-4. doi: 10.1055/s-2007-1023862.
4
A comparison of itraconazole versus fluconazole as maintenance therapy for AIDS-associated cryptococcal meningitis. National Institute of Allergy and Infectious Diseases Mycoses Study Group.伊曲康唑与氟康唑作为艾滋病相关隐球菌性脑膜炎维持治疗的比较。美国国立过敏与传染病研究所真菌病研究小组。
Clin Infect Dis. 1999 Feb;28(2):291-6. doi: 10.1086/515110.
5
[Choice and use of the new antifungal agents].[新型抗真菌药物的选择与应用]
Rev Clin Esp. 1994 Feb;194(2):116-27.
6
Clinical relevance of antifungal resistance.抗真菌药物耐药性的临床相关性。
Infect Dis Clin North Am. 1997 Dec;11(4):929-44. doi: 10.1016/s0891-5520(05)70398-6.
7
Activity of voriconazole, itraconazole, fluconazole and amphotericin B in vitro against 1763 yeasts from 472 patients in the voriconazole phase III clinical studies.伏立康唑III期临床研究中，伏立康唑、伊曲康唑、氟康唑和两性霉素B对472例患者的1763株酵母菌的体外活性。
Int J Antimicrob Agents. 2008 Dec;32(6):511-4. doi: 10.1016/j.ijantimicag.2008.05.023. Epub 2008 Sep 13.
8
[Antifungal agent resistance of yeasts of clinical significance].[具有临床意义的酵母对抗真菌剂的耐药性]
Rev Clin Esp. 1995 Oct;195 Suppl 3:56-7.
9
[Current progress in antifungal therapy: the value of fluconazole].[抗真菌治疗的当前进展：氟康唑的价值]
Rev Med Brux. 1990 Sep;11(7):278-82.
10
Fluconazole.氟康唑
J Infect. 1990 Jul;21(1):1-6. doi: 10.1016/0163-4453(90)90508-6.
Zotero 插件